Abstract
The COVID-19 pandemic increased utilization of telemedicine for diagnosis and treatment. While telemedicine is not the panacea for the increasing health care burden, it can alleviate the problem. Here, the hypothetical impact of delivering telehealth care to patients in a busy tertiary cardio-vascular clinic in Istanbul, Turkey, is examined. Additionally, the potential environmental and societal ramifications of telemedicine are also examined.
Demographics, health care costs, wages, productivity, and patient-specific data were exploited to develop a hypothetical telemedicine framework for the Turkish health care landscape. Specifically, the distance traveled and travel time to receive care using real-life location of the clinics and patients addresses seeking care are tabulated.
Data from August 3, 2015 to January 25, 2023 resulted in 45,602 unique encounters with 448 unique diagnoses recorded for the patient encounters. The patients in the top 5% of the most common diagnoses traveled 23.82 ± 96.3 km to reach the clinics. Based on our model and the related literature that telehealth care for chronic diseases is not inferior to face-to-face care, 656,258 km would have been saved if all patients were to take the first visit in person followed by telemedicine visits. The travel-associated carbon footprint and wage losses for in-person care in lieu of telehealth appointments is calculated and it was observed that exploiting telemedicine could have saved approximately 30% carbon footprint and prevented approximately $878,000 wage loss. As a result, it is found that application of telemedicine could ease the burden on patients, environment, increase access, and prevent the wage losses caused by unnecessary hospital visits.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted in accordance with the Declaration of Helsinki. The study was approved by the Institutional Review Board of the Halic University, Turkey (September 26, 2023; No. 212).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The address data will not be available.
